2,465 reports of this reaction
10.1% of all ESKETAMINE HYDROCHLORIDE reports
#2 most reported adverse reaction
SEDATION is the #2 most commonly reported adverse reaction for ESKETAMINE HYDROCHLORIDE, manufactured by Janssen Pharmaceuticals Inc.. There are 2,465 FDA adverse event reports linking ESKETAMINE HYDROCHLORIDE to SEDATION. This represents approximately 10.1% of all 24,470 adverse event reports for this drug.
Patients taking ESKETAMINE HYDROCHLORIDE who experience sedation should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
SEDATION is a frequently reported adverse event for ESKETAMINE HYDROCHLORIDE, accounting for a significant proportion of all reports.
In addition to sedation, the following adverse reactions have been reported for ESKETAMINE HYDROCHLORIDE:
The following drugs have also been linked to sedation in FDA adverse event reports:
SEDATION has been reported as an adverse event in 2,465 FDA reports for ESKETAMINE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
SEDATION accounts for approximately 10.1% of all adverse event reports for ESKETAMINE HYDROCHLORIDE, making it one of the most commonly reported side effect.
If you experience sedation while taking ESKETAMINE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.